179 related articles for article (PubMed ID: 32755379)
1. Integration of a 31-Gene Expression Profile Into Clinical Decision-Making in the Treatment of Cutaneous Melanoma.
Scott AM; Dale PS; Conforti A; Gibbs JN
Am Surg; 2020 Nov; 86(11):1561-1564. PubMed ID: 32755379
[TBL] [Abstract][Full Text] [Related]
2. Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary.
Johansson I; Tempel D; Dwarkasing JT; Rentroia-Pacheco B; Mattsson J; Ny L; Olofsson Bagge R
Eur J Surg Oncol; 2022 Feb; 48(2):320-325. PubMed ID: 34794843
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of the clinicopathologic and gene expression profile (CP-GEP) in patients with melanoma eligible for sentinel lymph node biopsy: A multicenter prospective Dutch study.
Stassen RC; Mulder EEAP; Mooyaart AL; Francken AB; van der Hage J; Aarts MJB; van der Veldt AAM; Verhoef C; Grünhagen DJ
Eur J Surg Oncol; 2023 Dec; 49(12):107249. PubMed ID: 37907016
[TBL] [Abstract][Full Text] [Related]
4. The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study.
Yamamoto M; Sickle-Santanello B; Beard T; Essner R; Martin B; Bailey CN; Guenther JM
Curr Med Res Opin; 2023 Mar; 39(3):417-423. PubMed ID: 36617959
[TBL] [Abstract][Full Text] [Related]
5. Management Decisions Made by Physician Assistants and Nurse Practitioners in Cutaneous Malignant Melanoma Patients: Impact of a 31-Gene Expression Profile Test.
Mirsky R; Prado G; Svoboda R; Glazer A; Rigel D
J Drugs Dermatol; 2018 Nov; 17(11):1220-1223. PubMed ID: 30500144
[TBL] [Abstract][Full Text] [Related]
6. Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma.
Mulder EEAP; Dwarkasing JT; Tempel D; van der Spek A; Bosman L; Verver D; Mooyaart AL; van der Veldt AAM; Verhoef C; Nijsten TEC; Grunhagen DJ; Hollestein LM
Br J Dermatol; 2021 May; 184(5):944-951. PubMed ID: 32844403
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit.
Grossman D; Okwundu N; Bartlett EK; Marchetti MA; Othus M; Coit DG; Hartman RI; Leachman SA; Berry EG; Korde L; Lee SJ; Bar-Eli M; Berwick M; Bowles T; Buchbinder EI; Burton EM; Chu EY; Curiel-Lewandrowski C; Curtis JA; Daud A; Deacon DC; Ferris LK; Gershenwald JE; Grossmann KF; Hu-Lieskovan S; Hyngstrom J; Jeter JM; Judson-Torres RL; Kendra KL; Kim CC; Kirkwood JM; Lawson DH; Leming PD; Long GV; Marghoob AA; Mehnert JM; Ming ME; Nelson KC; Polsky D; Scolyer RA; Smith EA; Sondak VK; Stark MS; Stein JA; Thompson JA; Thompson JF; Venna SS; Wei ML; Swetter SM
JAMA Dermatol; 2020 Sep; 156(9):1004-1011. PubMed ID: 32725204
[TBL] [Abstract][Full Text] [Related]
8. Impact of Gene Expression Profiling on Decision-Making in Clinically Node Negative Melanoma Patients after Surgical Staging.
Schuitevoerder D; Heath M; Cook RW; Covington KR; Fortino J; Leachman S; Vetto JT
J Drugs Dermatol; 2018 Feb; 17(2):196-199. PubMed ID: 29462228
[TBL] [Abstract][Full Text] [Related]
9. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma.
Keller J; Schwartz TL; Lizalek JM; Chang ES; Patel AD; Hurley MY; Hsueh EC
Cancer Med; 2019 May; 8(5):2205-2212. PubMed ID: 30950242
[TBL] [Abstract][Full Text] [Related]
10. Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy.
Arnot SP; Han G; Fortino J; Han D; Fowler G; Vetto JT
Am J Surg; 2021 Jun; 221(6):1195-1199. PubMed ID: 33773750
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a Gene Expression Profiling Assay in Primary Cutaneous Melanoma.
Kangas-Dick AW; Greenbaum A; Gall V; Groisberg R; Mehnert J; Chen C; Moore DF; Berger AC; Koshenkov V
Ann Surg Oncol; 2021 Aug; 28(8):4582-4589. PubMed ID: 33486642
[TBL] [Abstract][Full Text] [Related]
12. The 31-gene expression profile stratifies recurrence and metastasis risk in patients with cutaneous melanoma.
Jarell A; Skenderis B; Dillon LD; Dillon K; Martin B; Quick AP; Siegel JJ; Rackley BB; Cook RW
Future Oncol; 2021 Dec; 17(36):5023-5031. PubMed ID: 34587770
[TBL] [Abstract][Full Text] [Related]
13. Sentinel lymph node biopsy in cutaneous melanoma of the head and neck using the indocyanine green SPY Elite system.
Vahabzadeh-Hagh AM; Blackwell KE; Abemayor E; St John MA
Am J Otolaryngol; 2018; 39(5):485-488. PubMed ID: 29803536
[TBL] [Abstract][Full Text] [Related]
14. Validation of CP-GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: A U.S. cohort study.
Yousaf A; Tjien-Fooh FJ; Rentroia-Pacheco B; Quattrocchi E; Kobic A; Tempel D; Kolodney M; Meves A
Int J Dermatol; 2021 Jul; 60(7):851-856. PubMed ID: 33914348
[TBL] [Abstract][Full Text] [Related]
15. Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling.
Vetto JT; Hsueh EC; Gastman BR; Dillon LD; Monzon FA; Cook RW; Keller J; Huang X; Fleming A; Hewgley P; Gerami P; Leachman S; Wayne JD; Berger AC; Fleming MD
Future Oncol; 2019 Apr; 15(11):1207-1217. PubMed ID: 30691297
[TBL] [Abstract][Full Text] [Related]
16. Factors predicting survival in thick melanoma: Do all thick melanomas have the same prognosis?
Han D; Han G; Morrison S; Leong SP; Kashani-Sabet M; Vetto J; White R; Schneebaum S; Pockaj B; Mozzillo N; Sondak VK; Zager JS
Surgery; 2020 Sep; 168(3):518-526. PubMed ID: 32669204
[TBL] [Abstract][Full Text] [Related]
17. Excision margins and sentinel lymph node status as prognostic factors in thick melanoma of the head and neck: A retrospective analysis.
Ruskin O; Sanelli A; Herschtal A; Webb A; Dixon B; Pohl M; Donahoe S; Spillane J; Henderson MA; Gyorki DE
Head Neck; 2016 Sep; 38(9):1373-9. PubMed ID: 27014970
[TBL] [Abstract][Full Text] [Related]
18. Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update.
Wong SL; Faries MB; Kennedy EB; Agarwala SS; Akhurst TJ; Ariyan C; Balch CM; Berman BS; Cochran A; Delman KA; Gorman M; Kirkwood JM; Moncrieff MD; Zager JS; Lyman GH
Ann Surg Oncol; 2018 Feb; 25(2):356-377. PubMed ID: 29236202
[TBL] [Abstract][Full Text] [Related]
19. Sentinel lymph node biopsy for the T1 (thin) melanoma: is it necessary?
Nahabedian MY; Tufaro AP; Manson PN
Ann Plast Surg; 2003 Jun; 50(6):601-6. PubMed ID: 12783009
[TBL] [Abstract][Full Text] [Related]
20. Recurrence of cutaneous melanoma of the head and neck after negative sentinel lymph node biopsy.
Davis-Malesevich MV; Goepfert R; Kubik M; Roberts DB; Myers JN; Kupferman ME
Head Neck; 2015 Aug; 37(8):1116-21. PubMed ID: 24764188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
